Producto añadido correctamente al carrito.

discount label
H-HAKRRLIF-NH2
Ver en 3D

Biosynth logo

H-HAKRRLIF-NH2

Ref. 3D-PP43163

Tamaño no definidoA consultar
Entrega estimada en Estados Unidos, el Martes 3 de Diciembre de 2024

Información del producto

Nombre:
H-HAKRRLIF-NH2
Sinónimos:
  • NH2-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-amide
Descripción:

Peptide H-HAKRRLIF-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-HAKRRLIF-NH2 include the following: A novel approach to the design of selective inhibitors for cell cycle cyclin dependent kinases T Perkins - 2013 - search.proquest.comhttps://search.proquest.com/openview/fb15e7ad08e0ad72ac6b1b3c4f5eaa68/1?pq-origsite=gscholar&cbl=18750 Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update S Tadesse , EC Caldon , W Tilley - Journal of medicinal , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b01469 Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly S Liu , PN Premnath , JK Bolger, TL Perkins - Journal of medicinal , 2013 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm3013882 Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements S Liu , JK Bolger, LO Kirkland, PN Premnath - ACS chemical , 2010 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/cb1001262 Design of Non-ATP Competitive and Cell Cycle Specific CDK Inhibitors Targeting Cyclin Binding Groove S Liu - 2012 - scholarcommons.sc.eduhttps://scholarcommons.sc.edu/etd/1710/ Peptide Therapeutics: Oncology R Liu, X Li , TC Shih , JS Lee, KS Lam - 2017 - books.rsc.orghttps://books.rsc.org/books/edited-volume/661/chapter/357999 Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity PN Premnath , SN Craig, S Liu - Journal of Medicinal , 2015 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm5015023 Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy PN Premnath , SN Craig, S Liu , C McInnes - Bioorganic & medicinal , 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X16305650 Fragment based discovery of arginine isosteres through REPLACE: Towards non-ATP competitive CDK inhibitors PN Premnath , S Liu , T Perkins, J Abbott - Bioorganic & medicinal , 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0968089613009139 Development of inhibitors of protein-protein interactions through REPLACE: Application to the design and development non-atp competitive cdk inhibitors PN Premnath , S Craig, C McInnes - JoVE (Journal of Visualized , 2015 - jove.comhttps://www.jove.com/t/52441/development-inhibitors-protein-protein-interactions-through-replace Design and Development of a Novel Class of Cell Cycle CDK Inhibitors Targeting the Cyclin Binding Groove Utilizing the Replace Strategy PN Premnath - 2014 - scholarcommons.sc.eduhttps://scholarcommons.sc.edu/etd/2980/ Tumor-targeting peptides: ligands for molecular imaging and therapy N Zhao, Y Qin, H Liu, Z Cheng - Anti-Cancer Agents in , 2018 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/acamc/2018/00000018/00000001/art00012 REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors MJI Andrews, G Kontopidis , C McInnes , A Plater - , 2006 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cbic.200600189 Cyclin Dependent Kinase Inhibitors as Drug Targets for Cancer-A Review M Krishnaveni - researchgate.nethttps://www.researchgate.net/profile/Marimuthu-Krishnaveni/publication/320322652_Cyclin_Dependent_Kinase_Inhibitors_as_Drug_Targets_for_Cancer-A_Review/links/59de336caca27247d7942624/Cyclin-Dependent-Kinase-Inhibitors-as-Drug-Targets-for-Cancer-A-Review.pdf Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases M Klein - Pharmaceuticals, 2023 - mdpi.comhttps://www.mdpi.com/1424-8247/16/4/519 An overview on the prospective CDKs inhibitors as anti-cancer drugs KH Oudah , NS Abdou , RAT Serya - Journal of American , 2017 - researchgate.nethttps://www.researchgate.net/profile/Khulood-Oudah-2/publication/316158160_An_overview_on_the_prospective_CDKs_inhibitors_as_anti-cancer_drugs_Review_article/links/5bcd7d5b458515f7d9d02bdd/An-overview-on-the-prospective-CDKs-inhibitors-as-anti-cancer-drugs-Review-article.pdf Inhibition of the cell cycle with chemical inhibitors: A targeted approach JPI Welburn , JA Endicott - Seminars in cell & developmental biology, 2005 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1084952105000327 Εκφρalphaση κalphaι alphaποuόΜωση της alphaΜalphaσÏ ΜΎÏ alphaσuέΜης πρωτεΐΜης Cyclin A τοÏ  alphaΜΞρÏŜποÏ  στηΜ Escherichia coli κalphaι χalphaρalphaκτηρισuός της uε πιΞalphaΜούς alphaΜalphaστολείς Î’ ΝικολόποÏ λος - 2014 - ir.lib.uth.grhttps://ir.lib.uth.gr/xmlui/bitstream/handle/11615/44427/12642.pdf?sequence=1 Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A DI Zheleva, C McInnes , AL Gavine - Journal of peptide , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-3011.2002.21014.x Peptides or small molecules? Different approaches to develop more effective CDK inhibitors D Cirillo, F Pentimalli , A Giordano - Current medicinal , 2011 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2011/00000018/00000019/art00005 Cyclin dependent kinase (CDK) inhibitors as anticancer drugs C Sanchez-Martaca­nez, LM Gelbert, MJ Lallena - Bioorganic & medicinal , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X15005843 Peptidomimetic Design of CDK Inhibitors Targeting theRecruitment Site of the Cyclin Subunit C McInnes , MJ Andrews, DI Zheleva - -Anti-Cancer Agents, 2003 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmcaca/2003/00000003/00000001/art00007 REPLACE Strategy for Generating Non-ATP-Competitive Inhibitors of Cell Cycle Protein Kinases C McInnes - Protein-Protein Interactions in Drug Discovery, 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/9783527648207.ch12 Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones AI Grigoroudis, C McInnes , PN Premnath - Protein expression and , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1046592815000698 ATP-noncompetitive CDK inhibitors for cancer therapy: an overview AA Abate, F Pentimalli , L Esposito - Expert opinion on , 2013 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/13543784.2013.798641

Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:

Propiedades químicas

MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:

Información de peligrosidad

Número UN:
Cantidad exceptuada (EQ):
Clase:
Frases H:
Frases P:
Prohibido volar:
Información de peligrosidad:
Grupo de empaquetado:
Cantidad limitada (LQ):

Consulta técnica sobre: 3D-PP43163 H-HAKRRLIF-NH2

Use el carrito para solicitar presupuestos o pedidos

Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.

* Campos obligatorios
¡Bienvenido a CymitQuimica!Utilizamos cookies para mejorar su visita. No incluimos publicidad.

Consulte nuestra Política de Cookies para obtener más información o ajuste sus preferencias en "Configurar".